Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Bictegravir (BIC; GS-9883), a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase (IN), specifically targets IN strand transfer activity (50% inhibitory concentration [IC 50] of 7.5 ± 0.3 nM) and HIV-1 integration in cells. BIC exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concentrations ranging from 1.5 to 2.4 nM and selectivity indices up to 8,700 relative to cytotoxicity. BIC exhibits synergistic in vitro antiviral effects in pairwise combinations with tenofovir alafenamide, emtricitabine, or darunavir and maintains potent antiviral activity against HIV-1 variants resistant to other classes of antiretrovirals. BIC displayed an in vitro resistance profile that was markedly improved compared to the integrase strand transfer inhibitors (INSTIs) raltegravir (RAL) and elvitegravir (EVG), and comparable to that of dolutegravir (DTG), against nine INSTI-resistant site-directed HIV-1 mutants. BIC displayed statistically improved antiviral activity relative to EVG, RAL, and DTG against a panel of 47 patient-derived HIV-1 isolates with high-level INSTI resistance; 13 of 47 tested isolates exhibited >2-fold lower resistance to BIC than DTG. In dose-escalation experiments conducted in vitro, BIC and DTG exhibited higher barriers to resistance than EVG, selecting for HIV-1 variants with reduced phenotypic susceptibility at days 71, 87, and 20, respectively. A recombinant virus with the BIC-selected M50I/R263K dual mutations in IN exhibited only 2.8-fold reduced susceptibility to BIC compared to wild-type virus. All BIC-selected variants exhibited low to intermediate levels of cross-resistance to RAL, DTG, and EVG (<8-fold) but remained susceptible to other classes of antiretrovirals. A high barrier to in vitro resistance emergence for both BIC and DTG was also observed in viral breakthrough studies in the presence of constant clinically relevant drug concentrations. The overall virologic profile of BIC supports its ongoing clinical investigation in combination with other antiretroviral agents for both treatment-naive and -experienced HIV-infected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the last 14 years, four more INSTIs were approved for treatment of HIV infection: elvitegravir, dolutegravir, bictegravir and cabotegravir147–150.”
From Structure and function of retroviral integrase (2022) · cites this paper as [149]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708975 · Cited by 691
A quantitative assay for HIV DNA integration in vivo
Butler, S. L., Hansen, M. S. T., & Bushman, F. D. (2001) · Nature Medicine · doi:10.1038/87979 · Cited by 687
A three-dimensional model to analyze drug-drug interactions
Prichard, M. N., & Shipman, C. (1990) · Antiviral Research · doi:10.1016/0166-3542(90)90001-n · Cited by 544
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Raffi, F., Jaeger, H., Quiros-Roldan, E., Albrecht, H., Belonosova, E., Gatell, J. M., Baril, J.-G., Domingo, P., Brennan, C., Almond, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70257-3 · Cited by 379
Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01534-07 · Cited by 343
Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu051 · Cited by 333
Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P., Egbertson, M. S., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402357101 · Cited by 333
Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis750 · Cited by 311
The mechanism of retroviral integration from X-ray structures of its key intermediates
Maertens, G. N., Hare, S., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature09517 · Cited by 296
Malet, I., Delelis, O., Valantin, M.-A., Montes, B., Soulie, C., Wirden, M., Tchertanov, L., Peytavin, G., Reynes, J., Mouscadet, J.-F., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01228-07 · Cited by 283
A Packaging Cell Line for Lentivirus Vectors
Kafri, T., van Praag, H., Ouyang, L., Gage, F. H., & Verma, I. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.1.576-584.1999 · Cited by 256
Min, S., Song, I., Borland, J., Chen, S., Lou, Y., Fujiwara, T., & Piscitelli, S. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-09 · Cited by 244
Quashie, P. K., Mesplède, T., Han, Y.-S., Oliveira, M., Singhroy, D. N., Fujiwara, T., Underwood, M. R., & Wainberg, M. A. (2012) · Journal of Virology · doi:10.1128/jvi.06591-11 · Cited by 237
Koteff, J., Borland, J., Chen, S., Song, I., Peppercorn, A., Koshiba, T., Cannon, C., Muster, H., & Piscitelli, S. C. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04440.x · Cited by 196
Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy
McColl, D. J., & Chen, X. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.11.004 · Cited by 173
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action
Tsiang, M., Jones, G. S., Niedziela-Majka, A., Kan, E., Lansdon, E. B., Huang, W., Hung, M., Samuel, D., Novikov, N., Xu, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.347534 · Cited by 167
Self-citationLataillade, M., Chiarella, J., & Kozal, M. J. (2007) · Antiviral Therapy · doi:10.1177/135965350701200411 · Cited by 151
Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis
Messiaen, P., Wensing, A. M. J., Fun, A., Nijhuis, M., Brusselaers, N., & Vandekerckhove, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052562 · Cited by 131
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
Mesplède, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., Petropoulos, C. J., Huang, W., & Wainberg, M. A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-22 · Cited by 131
Zolopa, A. R., Berger, D. S., Lampiris, H., Zhong, L., Chuck, S. L., Enejosa, J. V., Kearney, B. P., & Cheng, A. K. (2010) · The Journal of Infectious Diseases · doi:10.1086/650698 · Cited by 113
Markowitz, M. H., Nguyen, B., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C. M., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181b064b0 · Cited by 111
Hurt, C. B., Sebastian, J., Hicks, C. B., & Eron, J. J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit697 · Cited by 111
Strategic design and three-dimensional analysis of antiviral drug combinations
Prichard, M. N., Prichard, L. E., & Shipman, C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.540 · Cited by 107
Elvitegravir: A New HIV Integrase Inhibitor
Shimura, K., & Kodama, E. N. (2009) · Antiviral Chemistry and Chemotherapy · doi:10.3851/imp1397 · Cited by 97
Cihlář, T., Ray, A. S., Boojamra, C. G., Zhang, L., Hui, H. C., Laflamme, G., Vela, J. E., Grant, D., Chen, J., Myrick, F. T., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01215-07 · Cited by 93
Self-citationEmerging patterns and implications of HIV-1 integrase inhibitor resistance
Geretti, A. M., Armenia, D., & Ceccherini‐Silberstein, F. (2012) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835a1de7 · Cited by 83
Wares, M., Mesplède, T., Quashie, P. K., Osman, N., Han, Y., & Wainberg, M. A. (2014) · Retrovirology · doi:10.1186/1742-4690-11-7 · Cited by 77
Margot, N., Hluhanich, R. M., Jones, G. S., Andreatta, K. N., Tsiang, M., McColl, D. J., White, K., & Miller, M. D. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.12.008 · Cited by 72
Self-citationThe development of novel HIV integrase inhibitors and the problem of drug resistance
Wainberg, M. A., Mésplède, T., & Quashie, P. K. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.007 · Cited by 71
Evolution of HIV integrase resistance mutations
Quashie, P. K., Mesplède, T., & Wainberg, M. A. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32835ba81c · Cited by 70
Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated Solvent Anchoring
Cihlář, T., He, G.-X., Liu, X., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.07.073 · Cited by 64
Garrido, C., Villacian, J., Zahonero, N., Pattery, T., Garcia, F., Gutierrez, F., Caballero, E., Van Houtte, M., Soriano, V., & de Mendoza, C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06170-11 · Cited by 64
HIV integrase as a target for antiretroviral therapy
Hazuda, D. J. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283567309 · Cited by 63
Resistance to HIV integrase inhibitors
Mésplède, T., Quashie, P. K., & Wainberg, M. A. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328356db89 · Cited by 63
Serrao, E., Krishnan, L., Shun, M.-C., Li, X., Cherepanov, P., Engelman, A., & Maertens, G. N. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku136 · Cited by 59
Next-Generation Integrase Inhibitors: Where to After Raltegravir?
Karmon, S. L., & Markowitz, M. H. (2013) · Drugs · doi:10.1007/s40265-013-0015-5 · Cited by 58
Jones, G. S., Yu, F., Zeynalzadegan, A., Hesselgesser, J., Chen, X., Chen, J., Jin, H., Kim, C. U., Wright, M., Geleziunas, R., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00984-08 · Cited by 57
Self-citationIntegrase inhibitors in the treatment of HIV-1 infection
Powderly, W. G. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq350 · Cited by 55
Wang, Y., Klock, H. E., Yin, H., Wolff, K. C., Bieza, K., Niswonger, K., Matzen, J., Gunderson, D., Hale, J., Lesley, S. A., et al. (2005) · SLAS DISCOVERY · doi:10.1177/1087057105275212 · Cited by 37
Huang, W., Frantzell, A., Fransen, S., & Petropoulos, C. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00204-13 · Cited by 30
Kulkarni, R., Abram, M. E., McColl, D. J., Barnes, T. L., Fordyce, M. W., Szwarcberg, J., Cheng, A., Miller, M. D., & White, K. (2014) · HIV Clinical Trials · doi:10.1310/hct1505-218 · Cited by 26
Self-citationNatural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance
Hachiya, A., Ode, H., Matsuda, M., Kito, Y., Shigemi, U., Matsuoka, K., Imamura, J., Yokomaku, Y., Iwatani, Y., & Sugiura, W. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.04.014 · Cited by 25
Xu, L., Liu, H., Hong, A. Y., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.057 · Cited by 25
S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges
Lenz, J. C. C., & Rockstroh, J. K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562189 · Cited by 22
White, K., Kulkarni, R., McColl, D. J., et al. (2014) · Antiviral Therapy · doi:10.3851/imp2885 · Cited by 21
Self-citation
Research works printed but not linked: 7
- Lepik KJ, Yip B, Robbins M, Woods C, Lima VD, McGovern RA, Zhang WW, Barrios R, Montaner JSG, Harrigan PR. 2016. Prevalence and incidence of integrase drug resistance in BC, Canada 2009-2015. Abstr 23rd Conf Retroviruses Opportunistic Infect, abstr 492LB.
- ViiV Healthcare. 2015. Tivicay 50 mg film-coated tablets. ViiV Healthcare, Middlesex, United Kingdom.
- Lazerwith SE, Cai R, Chen X, Desai MC, Eng S, Jacques R, Ji M, Martin H, McMahon C, Mish M, Morganelli P, Mwangi J, Pyun HJ, Schmitz U, Stepan G, Szwarcberg J, Tang J, Tsiang M, Wang J, White K, Wiser L, Zack J, Jin H. 2016. Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe 2016, poster 414.
- Pozniak A, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Hagins D, Buendia CB, Dorey D, Griffith S, Min S. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naive subjects: 24 week interim results from SAILING (ING111762). Abstr 20th Conf Retroviruses Opportunistic Infect, abstr 179LB.
- Jones G, Ledford RM, Yu F, Chen X, Miller MD, Tsiang M, McColl DJ. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstr 14th Conf Retroviruses Opportunistic Infect, abstr 627.
- Abram M, Margot N, Barnes T, Ram R, Chen X, White K, Miller M, Callebaut C. 2014. Clinical impact and characterization of HIV integrase inhibitor resistance associated with T97A: a low-level polymorphic integrase mutation, abstr POH-017. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- 10.1310/hct1504-218 · DOI
Cited by
Clinical targeting of HIV capsid protein with a long-acting small molecule
Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A., Hansen, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2443-1 · Cited by 425
Self-citation2015 update of the drug resistance mutations in HIV-1
Wensing, A. M. J., Cálvez, V., Ceccherini‐Silberstein, F., Charpentier, C., Günthard, H. F., Jacobsen, D. M., Paredes, R., Shafer, R. W., & Richman, D. D. (2015) · PubMed · doi:10.5167/uzh-122257 · Cited by 415
Sax, P. E., Pozniak, A., Montes, M. L., Koenig, E., DeJesus, E., Stellbrink, H.-J., Antinori, A., Workowski, K., Slim, J., Reynes, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32340-1 · Cited by 396
Self-citationGallant, J., Lazzarin, A., Mills, A., Orkin, C., Podzamczer, D., Tebas, P., Girard, P.-M., Brar, I., Daar, E. S., Wohl, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32299-7 · Cited by 393
Self-citationNext generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 313
Metadata
- Authors
- Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., Niedziela-Majka, A., Yant, S. R., Yu, H., Kukolj, G., Cihlar, T., Lazerwith, S. E., White, K. L., & Jin, H.
- Affiliations
- Gilead Sciences (United States) (US)
- Gilead Sciences, Foster City, California, USA
- Corresponding author
- White, Kirsten L.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7086-7097
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5118987
- OpenAlex
- W2523305619
- Cited by
- 290
- References
- 50
- Citations by year
- 2026: 19 · 2025: 26 · 2024: 24 · 2023: 25 · 2022: 24 · 2021: 40 · 2020: 37 · 2019: 38 · 2018: 36 · 2017: 18 · 2016: 2
- FWCI
- 28.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- bictegravir, antiviral activity, drug resistance, integrase inhibitors, dolutegravir, raltegravir, elvitegravir, cross-resistance, viral breakthrough, tenofovir alafenamide, emtricitabine, darunavir, drug selectivity
- MeSH terms
- Raltegravir Potassium, Dolutegravir, Amides, Cell Line, Drug Synergism, Heterocyclic Compounds, 3-Ring, Heterocyclic Compounds, 4 or More Rings, Humans, Mutation, Oxazines, Piperazines, Pyridones, HIV-1, Anti-HIV Agents, HIV Integrase, HIV Integrase Inhibitors, Drug Resistance, Viral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.